Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-04-02
2008-09-23
Richter, Johann (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S365000, C514S601000, C514S640000
Reexamination Certificate
active
07427633
ABSTRACT:
A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused byEscherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacterspecies,Serratia marcescensas well as those caused byBurkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistantPseudomonas aeruginosa, using a concentrated formulation of aztreonam lysinate delivered as an aerosol or dry powder formulation.
REFERENCES:
patent: 6660249 (2003-12-01), Montgomery
patent: 7138419 (2006-11-01), Montgomery et al.
patent: 7208141 (2007-04-01), Montgomery
patent: 7214364 (2007-05-01), Montgomery
patent: 0297580 (1999-01-01), None
Dietzsch et al. Pediatrics 1975, 55(1), 96-100.
Dapena Fenández et al. Spanish Annals of Medicine, 1994, 40(3).
Acevedo James H Alstrum
Gilead Sciences, Inc.
Richter Johann
Verny Hana
Verny, LLP Peters
LandOfFree
Inhalable aztreonam lysinate formulation for treatment and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhalable aztreonam lysinate formulation for treatment and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhalable aztreonam lysinate formulation for treatment and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3991486